CA2224859A1 - Inhibiteurs de ligands inhibant les proteines de liaison du facteur de croissance du type insuline et leurs procedes d'utilisation - Google Patents

Inhibiteurs de ligands inhibant les proteines de liaison du facteur de croissance du type insuline et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2224859A1
CA2224859A1 CA002224859A CA2224859A CA2224859A1 CA 2224859 A1 CA2224859 A1 CA 2224859A1 CA 002224859 A CA002224859 A CA 002224859A CA 2224859 A CA2224859 A CA 2224859A CA 2224859 A1 CA2224859 A1 CA 2224859A1
Authority
CA
Canada
Prior art keywords
insulin
growth factor
igf
igfbp
ligand inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002224859A
Other languages
English (en)
Inventor
Amitabh Gaur
Xin-Jun Liu
Nicholas Ling
Dominic Behan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2224859A1 publication Critical patent/CA2224859A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédés permettant d'augmenter le niveau des protéines libres biologiquement actives, y compris les facteurs de croissance du type insuline (IGF), et de traiter les états sensibles à l'IGF. Ces procédés consistent généralement à administrer un ou plusieurs inhibiteurs de ligands, qui inhibent la liaison de la protéine à une ou plusieurs protéines de liaison du facteur de croissance du type insuline. Les inhibiteurs de ligands appropriés comprennent les analogues de l'IGF-I ou l'IGF-II et les inhibiteurs moléculaires de petite taille.
CA002224859A 1996-04-17 1997-04-17 Inhibiteurs de ligands inhibant les proteines de liaison du facteur de croissance du type insuline et leurs procedes d'utilisation Abandoned CA2224859A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63393496A 1996-04-17 1996-04-17
US08/633,934 1996-04-17
PCT/US1997/006503 WO1997039032A1 (fr) 1996-04-17 1997-04-17 Inhibiteurs de ligands inhibant les proteines de liaison du facteur de croissance du type insuline et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
CA2224859A1 true CA2224859A1 (fr) 1997-10-23

Family

ID=24541756

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002224859A Abandoned CA2224859A1 (fr) 1996-04-17 1997-04-17 Inhibiteurs de ligands inhibant les proteines de liaison du facteur de croissance du type insuline et leurs procedes d'utilisation

Country Status (5)

Country Link
EP (1) EP0854884A1 (fr)
JP (1) JPH11508608A (fr)
AU (1) AU2676297A (fr)
CA (1) CA2224859A1 (fr)
WO (1) WO1997039032A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2276049A1 (fr) 1996-12-27 1998-07-09 Daiichi Pharmaceutical Co., Ltd. Procede pour elever la concentration de facteur de croissance libre apparente a l'insuline
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
WO2001072323A2 (fr) 2000-03-24 2001-10-04 Genentech, Inc. Utilisation de l'insuline pour traiter des affections des cartilages
EP1282437B1 (fr) 2000-05-16 2008-03-19 Genentech, Inc. Traitement des lesions du cartilage
WO2003049761A1 (fr) * 2000-12-08 2003-06-19 Neuronz Limited Utilisation du facteur de croissance 1 analogue a l'insuline pour favoriser la remyelinisation des axones
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
CA2478523A1 (fr) * 2002-04-05 2003-10-16 Euro-Celtique S.A. Matrice pour liberation prolongee, constante et independante de composes actifs
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN107921132B (zh) 2015-06-04 2021-05-07 圣拉斐尔医院有限公司 糖尿病和igfbp3/tmem219轴抑制剂
CN107921094B (zh) * 2015-06-04 2022-03-01 圣拉斐尔医院有限公司 Igfbp3及其用途
ES2863278T3 (es) 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Proteínas terapéuticas biespecíficas para la reparación de tejidos
WO2021005604A1 (fr) 2019-07-11 2021-01-14 Opko Biologics Ltd. Igf-1 ou variants d'igf-1 à action prolongée et procédés de production associés
WO2022216944A1 (fr) * 2021-04-07 2022-10-13 Mayo Foundation For Medical Education And Research Procédés et matériaux d'inversion de l'instabilité de la plaque d'athérome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000831A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne d'un facteur de croissance semblable a l'insuline

Also Published As

Publication number Publication date
WO1997039032A1 (fr) 1997-10-23
MX9710291A (es) 1998-08-30
EP0854884A1 (fr) 1998-07-29
JPH11508608A (ja) 1999-07-27
AU2676297A (en) 1997-11-07

Similar Documents

Publication Publication Date Title
CA2224859A1 (fr) Inhibiteurs de ligands inhibant les proteines de liaison du facteur de croissance du type insuline et leurs procedes d'utilisation
Baxter et al. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia
JP6581606B2 (ja) 選択的グルカゴン受容体アゴニストとしてのエキセンジン−４誘導体
AU634954B2 (en) Treatment of diabetes mellitus
DE60016560T2 (de) Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
CA2250075C (fr) Procedes pour diagnostiquer et traiter la maladie d'alzheimer
US20050176621A1 (en) Crystalline compositions for controlling blood glucose
US6610649B2 (en) Insulin C-peptides
US20110195896A1 (en) Isoform-specific insulin analogues
JP2008535797A (ja) ヒトレプチン由来のポリペプチドとその使用
US9149510B2 (en) Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
US20050054818A1 (en) Crystalline compositions for controlling blood glucose
JP2009542217A (ja) グルカゴン様ペプチドおよびその使用
US20100216693A1 (en) Compositions and methods of treating diabetes
JP2002521458A (ja) Ｉｇｆ／ｉｇｆｂｐ−３を用いた多嚢胞性卵巣症候群の治療方法
CN116322739A (zh) Glp-1r激动剂/fgf21融合蛋白
EP0580752A1 (fr) Proteine de liaison de facteurs de croissance analogues a l'insuline derivee d'os humain
JP2002526417A (ja) 非甲状腺性疾患の治療方法
AU1014400A (en) Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
WO1993021945A1 (fr) PROCEDES DE TRAITEMENT DE MALADIES VASCULAIRES AU MOYEN DE L'INHIBITION DE L'ACTIVITE DE STIMULATION DE L'ENDOTHELINE DE TGF$g(b)
WO1999049894A1 (fr) Antagonistes du gene 6 specifique de l'arret de croissance, et leur utilisation contre des troubles insulinoresistants
MXPA97010291A (en) Binding inhibitors of insulin type growth confactor fixation proteins and methods of use for myself
WO2022262837A1 (fr) Analogue du glucagon et son utilisation médicale
RU2523416C2 (ru) Применение аналогов соматостатина при менингиоме

Legal Events

Date Code Title Description
FZDE Dead